Ubaldo Jimenez loses no-hitter in seventh against Blue Jays

7 Comments

2:43 p.m. EDT: Brett Lawrie broke up the no-hitter with a two-run single to center with two outs in the seventh. The runners had previously moved up on a wild pitch, allowing the single to tie the game at 2.

Jimenez finished the seventh from there, but since he’s at 95 pitches now, there’s a good chance he’s done for the day.

2:40 p.m. EDT: Jimenez walked two of the first three batters in the seventh, leading to visit from the pitching coach and Rafael Perez getting up in the bullpen. The one out came despite Shin-Soo Choo losing a fly to right-center in the sun. Fortunately, center fielder Michael Brantley was able to step in and catch it.

///

Ubaldo Jimenez retired the first 17 batters he faced and has took a no-hitter into the seventh inning Saturday against the Blue Jays.

Jiemenz and Brandon Morrow actually had dueling no-hitters going into the bottom of the fifth. After Morrow started that frame with two quick outs, J.P. Arencibia committed a throwing error on Casey Kotchman’s grounder in front of the plate. It should have been the third out of the inning, but Jason Kipnis followed it with a two-run homer before Jack Hannahan struck out.

Jimenez didn’t allow a baserunner of any sort until Colby Rasmus walked with two outs in the sixth. He’s at 75 pitches through six.

The exceptional outing follows an exhibition season in which Jimenez allowed 24 runs — 19 earned — and 30 hits in 23 innings. He struck out 15 and walked 15 in his seven starts.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.